WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Abrir esta carpeta y ver su contenidoInsect and arachnid bites and stings
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Abrir esta carpeta y ver su contenidoViral infections
Cerrar esta carpetaEczematous diseases
Ver el documentoContact dermatitis
Ver el documentoAtopic dermatitis
Ver el documentoSeborrhoeic dermatitis
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Abrir esta carpeta y ver su contenidoPremalignant lesions and malignant tumours
Abrir esta carpeta y ver su contenidoPhotodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Abrir esta carpeta y ver su contenidoAnti-inflammatory and antipruritic drugs1
Abrir esta carpeta y ver su contenidoAntiallergics and drugs used in anaphylaxis
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Atopic dermatitis

Atopic dermatitis, which often develops within the first few months of life, is a disease of unknown etiology. However, in many cases T-cell function is defective and serum IgE concentrations are elevated, which suggest that the immunological system is involved. Blockade of cutaneous β-adrenoreceptors has also been described. Other members of the immediate family are commonly affected, and relatives may have or may develop allergic rhinitis or asthma. The condition usually resolves spontaneously between the age of 5 and 8 years but it may persist into adulthood. Exacerbations may occur during periods of physical or emotional stress.

Weeping eczematous papules that are intensely pruritic develop in the face in infants, particularly on the cheeks. These lesions often extend to other skin surfaces later in childhood, including the scalp, wrists, flexor folds of the elbows and knees, and buttocks. Scratching leads to the formation of excoriations and infiltrated areas which subsequently become thickened or lichenified. Later, the lesions become drier, more scattered, and typically localized in the flexor folds of the neck, elbows, wrists and knees. Pustules and crusts are signs of secondary infection. Periorbital erythema and oedema are common.

Prevention and management

It is particularly important to explain to parents the chronic, relapsing nature of the disease and the factors that influence its course. Soaps, particularly those containing irritants or perfumes, should be avoided when washing children. Contact with detergents, domestic animals and clothes made from wool should also be avoided. Pruritus may be partially relieved by applying wet dressings to exudative lesions and emollients to lichenified plaques. If topical hydrocortisone, 1% concentration, is ineffective, the use of betamethasone valerate, other corticosteroids of comparable potency, or more potent corticosteroids such as oral prednisolone should be undertaken with care and with time-limitations to avoid side-effects. Topical antihistamines are not effective and should be avoided because of the risk of sensitization. However, oral antihistamines, particularly hydroxyzine, can be given at night to relieve pruritus and to facilitate sleep. Non-sedating antihistamines can be given during the day, and may provide some symptomatic relief. Since secondary staphylococcal infections, which can be subclinical or clinical, are common and can cause exacerbations, an oral antibiotic such as erythromycin can be given for 7-10 days (see Erythromycin - Dosage and administration), or a topical antibiotic such as mupirocin ointment can be applied to the skin.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 19 enero 2012